Scholar Rock Holding Corporation
SRRK
Classement en actions
#3423
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Prix de l'action
$41.58
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$5.06B
Changement (1 jour)
3.34%
Changement (1 an)
47.62%
Pays
US
Échange Scholar Rock Holding Corporation (SRRK)
Catégorie
Healthcare
Ratio P/S pour Scholar Rock Holding Corporation (SRRK)
Ratio P/S au October 2026 TTM : 0.00
Selon les derniers rapports financiers et le cours de l'action de Scholar Rock Holding Corporation, le ratio cours/ventes actuel (TTM) est 0.00. À la fin de 2023, le ratio P/S était de 0.00.
Historique du ratio P/S pour Scholar Rock Holding Corporation de 2016 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 16.25 | -66.46% |
| 2021 | 48.47 | -49.95% |
| 2020 | 96.83 | 446.72% |
| 2019 | 17.71 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | 732.28 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
